FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical compositions containing (2-hydroxyethoxy)amide 6-(4-brom-2-chlorophenylamino)-7-fluor-3-methyl-3H-benzoimidazole-5-carboxylic acid hydrosulphate and solvates, crystalline forms and amorphous forms thereof, to using the above compositions as a drug; and to methods for preparing the above compositions.
EFFECT: preparing the new pharmaceutical compositions.
20 cl, 7 tbl, 7 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING TAXANES AND METHODS FOR TREATMENT USING THEREOF | 1999 |
|
RU2236226C2 |
| TRANSBUCCAL DELIVERY SYSTEM | 2006 |
|
RU2406480C2 |
| NOVEL HYDROSULPHATE SALT | 2006 |
|
RU2418790C2 |
| SEMIFIRM SYSTEMS CONTAINING DERIVATIVES OF AZETIDINUM | 2004 |
|
RU2343915C2 |
| NEW PHARMACEUTICAL COMPOSITION CONTAINING NONIONIC SURFACTANTS | 2015 |
|
RU2720680C2 |
| PHARMACEUTICAL DOSED FORM FOR PERORAL INTRODUCTION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2568599C2 |
| PHARMACEUTICAL COMPOSITION DESIGNATED FOR ORAL ADMINISTRATION OF PYRAZOLE-3-CARBOXAMIDE DERIVATIVE | 2004 |
|
RU2321404C1 |
| PHARMACEUTICAL COMPOSITION OF TAXOIDS | 2011 |
|
RU2603833C2 |
| PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2711359C2 |
| PHARMACEUTICAL DRUG FORM OF TYROSINE KINASE INHIBITOR FOR PERORAL INTRODUCTION | 2007 |
|
RU2468788C2 |
